SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precious metals surge amid economic uncertainty, outperforming retreating cryptos as safer investments in 2026. It's your time to stack some Digital $METALS

Digital Metals

METALS CRYPTO is trending due to its recent volatile price action, sparking intense debate and divided opinions within the investment community. While some users are reporting significant overnight gains and anticipating a parabolic rally, a vocal segment expresses strong skepticism, warning of a potential rug pull and likening it to broader questionable trends within the crypto space.

Definium Therapeutics Inc.

Definium Therapeutics (DFTX) is gaining traction after its recent ticker update, with community discussion highlighting legislative progress in the psychedelic sector. Recent state-level psilocybin legislation favoring FDA-aligned and physician-led models is creating a bullish outlook for synthetic psychedelic companies like DFTX. Investors are actively debating the long-term potential and implications for the industry amidst these evolving regulatory landscapes.

Icahn Enterprises LP operates as holding company. It operates through following eight business segments: Investment, Automotive, Energy, Food Packaging, Metals, Real Estate, Home Fashion, and Pharma. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group LLC. The Energy segment holds ownership in CVR Energy, Inc., which owns majority interests in two separate operating subsidiaries, CVR Refining, LP and CVR Partners, LP. The Food Packaging segment holds ownership in Viskase Cos., Inc., which is engaged in the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Metals segment operates through PSC Metals, Inc., which engages in the business of collecting, processing, and selling ferrous and non-ferrous metals, as well as the processing and distribution of steel pipe and plate products in the Midwest and Southern U.S. The Real Estate segment consists of rental real estate, property development and resort activities. The Home Fashion segment operates through WestPoint Home LLC, which consists of manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operates through Vivus, Inc., a specialized pharmaceutical company. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

Icahn Enterprises is trending amid anticipation of a rebound, primarily driven by strong performance from its significant CVR Energy (CVI) holding, which is benefiting from favorable regulatory developments and robust earnings. Community discussion highlights the stock's high short interest, sparking speculation of a potential squeeze, while some investors remain attracted to its substantial dividend yield despite past volatility. Many believe Icahn's recent portfolio adjustments and improving asset values could signal a broader recovery for IEP.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending amidst intense community debate sparked by a controversial ICE shooting incident in Minnesota, fueling widespread discussion on government actions and civil liberties. The discourse is sharply polarized, with some demanding accountability and criticizing perceived overreach, while others commend law enforcement efforts to maintain order. Additionally, the symbol's namesake is drawing attention for recent threats of tariffs against Canada regarding their trade policies with China, underscoring broader geopolitical tensions impacting market sentiment.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

GASS is trending due to its strong association with Matt Furie, the creator of $PEPE, sparking community excitement that GasspasCat could emerge as a notable player in the meme coin arena. Discussions highlight its perceived early-stage potential, with many advocating to "hodl" for future growth and drawing comparisons to the trajectory of other successful meme tokens. The narrative surrounding its artistic origins and low market capitalization continues to drive investor conversation.

PAX Gold (PAXG) is an asset-backed token where one token should represent one fine troy ounce of a London Good Delivery gold bar, stored in professional vault facilities. Anyone who owns PAXG has ownership rights to that gold under the custody of Paxos Trust Company. Since PAXG represents physical gold, its value is tied directly to the real-time market value of that physical gold.  PAXG gives customers the benefits of actual physical ownership of specific gold bars with the speed and mobility of a digital asset. Customers are able to have fractional ownership of physical bars. On the Paxos platform, customers can convert their tokens to allocated gold, unallocated gold, or fiat currency (and vice versa) quickly and efficiently, reducing their exposure to settlement risk. PAXG is also available for trading on Paxos’ itBit exchange. PAXG will also be available on other crypto-asset exchanges, wallets, lending platforms and elsewhere within the crypto ecosystem.   At any time, PAXG holders can lookup the serial number, value and physical characteristics of their vaulted gold just by entering their Ethereum wallet address on the PAXG lookup tool on Paxos.com/paxgold.

PAX Gold

PAX Gold is trending as investors seek stable, asset-backed alternatives amid broader market uncertainty and skepticism toward traditional financial systems. The community is actively debating its role as a transparent "digital gold" versus Bitcoin, with many considering it a reliable hedge against fiat currency devaluation and the perceived risks of traditional "paper gold" investments.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as the community eagerly discusses its strategic move to acquire a bank charter and a confirmed Coinbase listing, which are seen as pivotal for its integration with traditional finance. Investors are highlighting the project's robust, compliant financial infrastructure, boasting capabilities like 11 million TPS and native fiat rails, backed by notable industry figures.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is gaining significant attention amid optimism surrounding its QNX technology, particularly its deep integration into software-defined vehicles with new partnerships like BMW's Neue Klasse and Mercedes-Benz. The community is actively debating QNX's accelerating growth, evidenced by expanding vehicle deployments and innovative offerings like Alloy Kore, against persistent concerns about overall company revenue and leadership's ability to fully monetize these advancements.

Rio Tinto Plc engages in the exploration, mining, and processing of mineral resources. It operates through the following business segments: Iron Ore, Aluminium, Copper, and Minerals. The Iron Ore segment supplies iron ore mining and salt and gypsum production. The Aluminium segment produces bauxite, alumina and primary aluminum. The Copper segment offers gold, silver, molybdenum and other by-products. The Minerals includes businesses with products such as uranium, borates, salt and titanium dioxide feedstock together with coal operations. The Other Operations segment covers the curtailed Gove alumina refinery and Rio Tinto Marine operations. The company was founded in 1873 and is headquartered in London, the United Kingdom.

Rio Tinto plc - ADR

Rio Tinto plc

Rio Tinto is gaining significant attention following its innovative partnership with Amazon Web Services, which will utilize its low-carbon Nuton copper for US data centers, signaling a major leap in sustainable technology. The community is actively discussing RIO's pivotal role in supplying critical minerals for electrification and AI infrastructure, viewing it as an undervalued long-term investment poised for further growth. Many highlight its strong dividend and recent technical breakouts as reasons for optimism in the booming commodities sector.

ProShares Trust - ProShares UltraPro Short S&P 500

ProShares UltraPro Short S&P 500 ETF

SPXU is trending as market participants eye increasing geopolitical tensions and renewed tariff talks that could trigger a significant market pullback. Many traders are actively debating whether current market highs are sustainable, positioning SPXU as a key hedging instrument or direct play on a potential broad market decline. Concerns about overvaluation are driving conversations around this inverse S&P 500 ETF.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$VBIV Based on the following recent events, it seems like GSK is getting more serious about VBIV&#39;s CMV/GBM IP. IMO, these events could easily qualify GSK as an emerging candidate for a partnership for our CMV/Oncology IP or even as a potential acquirer.
  
a. GSK co-filing of a new US-20210069321 patent application with VBIV for the Immunotherapeutic Composition consists of our 1901 IP with GSK&#39;s adjuvant.

Investor

Brown Mamba

🖐️- SOME. 🔥🐻🔥

SephieV

S2H2

Jackson Card

Master of the Hum Hum Hum

AskSlapper

Wades World

Sy Huss

Cleo

Tobyornotoby

Adnan

Mr_Simpson

Pavel Hýža

Christopher Harvey

G37X

Nobody

Michal

Dmitry

RonBoBull

Mostly Equity

Jacob Knippenberg

ES Collier

OKGGG

john smith

StockTwits Web

VBI Vaccines Inc.

 Based on the following recent events, it seems like GSK is getting more serious about VBIV's CMV/GBM IP. IMO, these events could easily qualify GSK as an emerging candidate for a partnership for our CMV/Oncology IP or even as a potential acquirer.
  
a. GSK co-filing of a new US-20210069321 patent application with VBIV for the Immunotherapeutic Composition consists of our 1901 IP with GSK's adjuvant.

 b. The same patent was filed across three jurisdictions within a week apart from each other (Canada on March 8, 2021, the USA on March 10, 2021, and WO-Worldwide on March 17, 2021)

Emmo Silver

JGMoney

Ardesco

David

Armin

Maurizio (ita)

Mr Nguyen

Johnny

Fikret Mirzoyev

 c. Unlike VBIV&#39;s 1901 related IP patent US-20200376113, which was filed only in the US on December 3, 2020, the co-filed GSK patent goes into a full length, claiming the patent&#39;s applicability to other oncology indications such as breast, colon, ovarian, and prostate cancer, rhabdomyosarcoma, hepatocellular cancer, salivary gland tumors, neuroblastoma, and brain tumors.

 c. Unlike VBIV's 1901 related IP patent US-20200376113, which was filed only in the US on December 3, 2020, the co-filed GSK patent goes into a full length, claiming the patent's applicability to other oncology indications such as breast, colon, ovarian, and prostate cancer, rhabdomyosarcoma, hepatocellular cancer, salivary gland tumors, neuroblastoma, and brain tumors.

 Outlined claims of VBIV&#39;s US-20200376113 patent:

M. Finch

whynot2day

 Outlined claims of VBIV's US-20200376113 patent:

 Outlined claims of GSK&#39;s US-20210069321 patent for 1901 IP:

 Outlined claims of GSK's US-20210069321 patent for 1901 IP:

 d. The fact that Kirsten Schneider-Ohrum is listed on the patent as a co-inventor along with David, where she has no connection to neither underlying IP nor the GSK&#39;s AS01 adjuvant used in it, says a lot about this patent&#39;s intention.  IMO, the real purpose is an initiation of IP transfer from VBIV to GSK.

Jay Ell

BenjiCool

 d. The fact that Kirsten Schneider-Ohrum is listed on the patent as a co-inventor along with David, where she has no connection to neither underlying IP nor the GSK's AS01 adjuvant used in it, says a lot about this patent's intention.  IMO, the real purpose is an initiation of IP transfer from VBIV to GSK.

 e.  Also, Kirsten Schneider-Ohrum&#39;s sudden move from her previous position, where one of her responsibilities was enabling revenue growth by accurately forecasting the evolution of new vaccines and identifying profitable vaccines... now to head cytomegalovirus vaccine development bods well with the point d. above.

 e.  Also, Kirsten Schneider-Ohrum's sudden move from her previous position, where one of her responsibilities was enabling revenue growth by accurately forecasting the evolution of new vaccines and identifying profitable vaccines... now to head cytomegalovirus vaccine development bods well with the point d. above.

 f. The timing aspect of Kirsten Schneider-Ohrum&#39;s promotion (January of 2021) to head CMV-based vaccine development in correlation with our ongoing 1901 clinical trials&#39; positive progress right around the same time.

Karol Wy

 f. The timing aspect of Kirsten Schneider-Ohrum's promotion (January of 2021) to head CMV-based vaccine development in correlation with our ongoing 1901 clinical trials' positive progress right around the same time.

 g. VBIV&#39;s secrecy around undisclosed preclinical study for &quot;Other CMV+ Tumors&quot; paired with the points a. b. c. d. e. f. now starts making more sense.

Jefferson Carrol

 g. VBIV's secrecy around undisclosed preclinical study for "Other CMV+ Tumors" paired with the points a. b. c. d. e. f. now starts making more sense.

 h. GSK&#39;s recent ADR&#39;s issuance on March 15, 2021, and Automatic Shelf registration on March 26, 2021, might be a good indicator of them getting ready to finance upcoming partnership or BO.

 h. GSK's recent ADR's issuance on March 15, 2021, and Automatic Shelf registration on March 26, 2021, might be a good indicator of them getting ready to finance upcoming partnership or BO.

@bmkb24  I sent you a message in private chat.  You&#39;re definitely onto something... Thank you for this amazing post, ill read it again tomorrow AM and break it down with @ChugNorris

Mr. Investor

BioJoy

StockTwits For Android 

  I sent you a message in private chat.  You're definitely onto something... Thank you for this amazing post, ill read it again tomorrow AM and break it down with 

WEIBO

@bmkb24 you sir, are a blessing to this community. Thanks for this wonderful DD. Sure beats my speculative interpretation of common knowledge. GLTA.

 you sir, are a blessing to this community. Thanks for this wonderful DD. Sure beats my speculative interpretation of common knowledge. GLTA.

Clever Leaves Holdings Inc

@Xtrykr anytime brother, always happy to share my findings :)

Andrew

 anytime brother, always happy to share my findings :)

@bmkb24 I couldn&#39;t help but notice the filing date vs the publication dates where these patent applications were published within about 6-12 months of filing. That is very fast! Normally from filing to publishing takes 18 months. Was there some sort of priority given to these series of patents to have the patent office churn them out so quickly?

 I couldn't help but notice the filing date vs the publication dates where these patent applications were published within about 6-12 months of filing. That is very fast! Normally from filing to publishing takes 18 months. Was there some sort of priority given to these series of patents to have the patent office churn them out so quickly?

@Xtrykr it&#39;s quite possible that they applied for USPTO&#39;s prioritized examination path...

Joon

 it's quite possible that they applied for USPTO's prioritized examination path...

@bmkb24 @Xtrykr this would be a perfect scenario to an already perfect situation.

 this would be a perfect scenario to an already perfect situation.

GameStop Corp

@bmkb24 $VBIV El, wow, thanks a lot, awesome and very telling find indeed! The joint GSK-VBIV US-20210069321 patent application has a filling date of Sep 8th, 2020. As you may remember, VBI Vaccines B.V. was registered in NL in the end of Oct 2020. These two events could be related. E.g., Tesaro BO by GSK also involved a Dutch incorporation of Tesaro two years before it has occurred.

 El, wow, thanks a lot, awesome and very telling find indeed! The joint GSK-VBIV US-20210069321 patent application has a filling date of Sep 8th, 2020. As you may remember, VBI Vaccines B.V. was registered in NL in the end of Oct 2020. These two events could be related. E.g., Tesaro BO by GSK also involved a Dutch incorporation of Tesaro two years before it has occurred.

@bmkb24 since the interview, news isn&#39;t their game plan.. important events such as their Israel client purchasing 1yr advance stock of HepB vaccines is significantly news worthy. They do not showcase either which and then they hit with events like CEPI, events with BRii etc ,  the IR of the company lags but still a great company to discover..

 since the interview, news isn't their game plan.. important events such as their Israel client purchasing 1yr advance stock of HepB vaccines is significantly news worthy. They do not showcase either which and then they hit with events like CEPI, events with BRii etc ,  the IR of the company lags but still a great company to discover..

Revive Therapeutics Ltd

@bmkb24 Thank you El! Some world-class DD.  Not worried about this low volume bio SP bleed, but your posts always make the dreary days much better. Thanks bro.

Stephanie

Sam The Seed

 Thank you El! Some world-class DD.  Not worried about this low volume bio SP bleed, but your posts always make the dreary days much better. Thanks bro.

Biocryst Pharmaceuticals Inc.

Advanced Micro Devices Inc

SPDR S&P Biotech ETF

TG Therapeutics Inc

DraftKings Inc

CoreWeave Inc

Brunt - F.C.A.

@bmkb24 best DD I have seen on here in a while thank you!

StockTwits for iOS

 best DD I have seen on here in a while thank you!

Ault Alliance Inc

John Daugherty

@stau Anytime bro. Btw, excellent association with the B.V. event... Another similarity with the Tesaro acquisition is that in the same year of that BO, GSK initiated automatic shelf registration F-3ASR on March 27, 2018, followed by the cascade of other prospectus-based filings to help raise cash. Here is the chronological list of those filings, starting with the March 27 shelf registration filing and ending with the tender drop on  on December 3, 2018.

$VBIV Don&#39;t let them steal your shares. Extremely bullish.

 Anytime bro. Btw, excellent association with the B.V. event... Another similarity with the Tesaro acquisition is that in the same year of that BO, GSK initiated automatic shelf registration F-3ASR on March 27, 2018, followed by the cascade of other prospectus-based filings to help raise cash. Here is the chronological list of those filings, starting with the March 27 shelf registration filing and ending with the tender drop on  on December 3, 2018.

@bmkb24 Thank you for the update and condensation of information. I wouldn&#39;t have had the chance at all or experience to get something like this together. CHeers

 Thank you for the update and condensation of information. I wouldn't have had the chance at all or experience to get something like this together. CHeers

Energy Fuels Inc

@bmkb24  Thanks for sharing your hard work.

ImmunityBio Inc

@C0ffeeB34n @glimdbea anytime guys, always happy to share :)

Although GSK does not actively pursue any CMV IP after they put a halt on the one they had due to insufficient efficacy... The recent activity around hiring/promoting senior CMV personnel is very telling. 

Senior Director, Clinical Development Vaccines - Cytomegalovirus
https://jobs.gsk.com/en-gb/jobs/273700?lang=en-us

Although GSK does not actively pursue any CMV IP after they put a halt on the one they had due to insufficient efficacy... The recent activity around hiring/promoting senior CMV personnel is very telling. 

Senior Director, Clinical Development Vaccines - Cytomegalovirus


@bmkb24 El, I found that in June 2020 GSK has submitted another patent regarding the use of the CHO mammalian cells for production CMV antigens (and which was published in Sep 2020):
https://www.lens.org/lens/patent/170-868-410-347-228

The Lens serves almost all the patents and scholarly work in the world as a free, open and secure digital public good, with user privacy a paramount focus.

The Lens - Free & Open Patent and Scholarly Search

HR P20200932 T1 - Mammalian Cells Expressing Cytomegalovirus Antigens The Lens - Free & Open Patent and Scholarly Search

 El, I found that in June 2020 GSK has submitted another patent regarding the use of the CHO mammalian cells for production CMV antigens (and which was published in Sep 2020):
